Pan-KRAS Inhibitor YL-17231

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of various KRAS mutations, such as the oncogenic KRAS substitution mutations G12C, G12D and G12V, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor YL-17231 targets, binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent signaling. This inhibits the proliferation of and induces apoptosis in tumor cells in which KRAS is mutated. KRAS plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

**Synonyms:** - Pan-KRAS Mutant Inhibitor YL-17231 - RAS Inhibitor YL-17231 - TEB 17231 - TEB-17231 - TEB17231 - YL 17231 - YL-17231 - YL17231